Effects of Sequential Influenza A(H1N1)pdm09 Vaccination on Antibody Waning

Zelner, Jon; Petrie, Joshua G.; Trangucci, Rob; Martin, Emily T.; Monto, Arnold S.

doi:10.1093/infdis/jiz055

Cited by 12 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this trial that directly compared clinical efficacy and HAI titers over one season, the rate of VE waning was generally consistent with the rate of antibody decay (Petrie et al 2016). For A(H1N1)pdm09, antibody decay increased with repeated vaccination, although the antibody half-life exceeded the length of a typical influenza season among persons with repeated vaccination (Zelner et al 2019).…”

Section: Influenza Vaccine Effectivenesssupporting

confidence: 57%

Influenza Vaccine Effectiveness: New Insights and Challenges

McLean

Belongia

2020

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

Methods for assessing influenza vaccine efficacy and effectiveness have evolved over six decades. Randomized trials remain the gold standard for licensure, but observational studies are needed for annual assessment of vaccine effectiveness (VE). The test-negative design (TND) has become the de facto standard for these field studies. Patients who seek medical care with acute respiratory illness are tested for influenza, and VE is estimated from the odds of vaccination among influenza cases versus test-negative controls. VE varies across seasons, populations, age groups, and products, but VE estimates are consistently higher for A(H1N1) pdm09 and type B compared with A(H3N2). VE studies are increasingly used in combination with molecular epidemiology to understand the viral and immune system factors that drive clinical efficacy and effectiveness. The emerging field of immunoepidemiology offers the potential to understand complex host-virus interactions that affect vaccine protection, and this knowledge will contribute to universal vaccine development.

show abstract

Section: Influenza Vaccine Effectivenesssupporting

confidence: 57%

Influenza Vaccine Effectiveness: New Insights and Challenges

McLean

Belongia

2020

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

show abstract

“…Current licensed seasonal influenza virus vaccines are formulated as inactivated influenza virus vaccines (IIV), live-attenuated influenza virus vaccines (LAIV), or recombinant hemagglutinin (HA) proteins [ 5 ]. In general, seasonal influenza vaccines provide immunity against infection by influenza viruses that antigenically match the vaccine strains [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ]. The effectiveness of seasonal influenza vaccines to prevent laboratory-confirmed influenza varies by influenza season (with estimates ranging from 10 to 60%), with an estimate of 29% for the overall effectiveness of the 2018–2019 seasonal influenza vaccines [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model

et al. 2021

View full text Add to dashboard Cite

Epidemic or pandemic influenza can annually cause significant morbidity and mortality in humans. We developed novel chimeric hemagglutinin (cHA)-based universal influenza virus vaccines, which contain a conserved HA stalk domain from a 2009 pandemic H1N1 (pH1N1) strain combined with globular head domains from avian influenza A viruses. Our previous reports demonstrated that prime-boost sequential immunizations induced robust antibody responses directed toward the conserved HA stalk domain in ferrets. Herein, we further followed vaccinated animals for one year to compare the efficacy and durability of these vaccines in the preclinical ferret model of influenza. Although all cHA-based immunization regimens induced durable HA stalk-specific and heterosubtypic antibody responses in ferrets, sequential immunization with live-attenuated influenza virus vaccines (LAIV-LAIV) conferred the best protection against upper respiratory tract infection by a pH1N1 influenza A virus. The findings from this study suggest that our sequential immunization strategy for a cHA-based universal influenza virus vaccine provides durable protective humoral and cellular immunity against influenza virus infection.

show abstract

“…Epidemiological studies have evaluated the clinical effectiveness of seasonal influenza immunization among persons who had repeated annual vaccinations during different seasons, with several analyses showing poor vaccine efficacy among this group [ 18 , 19 , 20 , 21 , 22 , 23 ]. However, other analyses demonstrated continued protection with repeated annual influenza vaccination [ 24 , 25 ], or determined that the evidence is inconclusive to advise against repeated influenza vaccination [ 26 , 27 ]. Thus, there are discrepant results and the underlying immune characteristics affecting those who have been repeatedly vaccinated, as compared with persons who are minimally vaccinated or unvaccinated, are not well described.…”

Section: Introductionmentioning

confidence: 99%

The Effects of Imprinting and Repeated Seasonal Influenza Vaccination on Adaptive Immunity after Influenza Vaccination

et al. 2020

View full text Add to dashboard Cite

(1) Background: The influenza virus continues to cause significant annual morbidity and mortality. The overall efficacy of seasonal influenza vaccination is suboptimal, which is partly due to host immune factors. The effects of imprinting and repeated seasonal influenza vaccination were investigated to assess for immune factors and mechanisms that impact influenza vaccine responses. (2) Methods: Twenty participants were enrolled into a prospective pilot study based on birth cohort and seasonal influenza immunization history. Immunologic parameters were assessed over a six-month period after the seasonal influenza vaccine was administered. (3) Results: There was no significant imprinting effect, as measured by hemagglutination inhibition (HAI) fold change, HAI geometric mean titer (GMT) for Day 29 or Day 180 post-vaccination and antigen- specific antibody-secreting cells (ASC) for Day 8 post-vaccination. Individuals who had minimal prior seasonal influenza vaccination had a higher magnitude ASC response and a higher HAI fold change post-vaccination than individuals who were repeatedly vaccinated. (4) Conclusions: Repeated seasonal influenza vaccination resulted in a decreased fold change of the immune response, although individuals in this cohort tended to have high HAI titers at baseline that persisted after vaccination. Imprinting effects were not observed in this cohort. These host immune factors should be considered in the development of universal influenza vaccines. ClinicalTrials.gov Identifier: NCT03686514

show abstract

Effects of Sequential Influenza A(H1N1)pdm09 Vaccination on Antibody Waning

Cited by 12 publications

References 34 publications

Influenza Vaccine Effectiveness: New Insights and Challenges

Influenza Vaccine Effectiveness: New Insights and Challenges

Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model

The Effects of Imprinting and Repeated Seasonal Influenza Vaccination on Adaptive Immunity after Influenza Vaccination

Contact Info

Product

Resources

About